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A B S T R A C T
Myocardial ischemia is diﬃcult to diagnose eﬀectively with still few well-deﬁned biochemical markers for
identiﬁcation in advance, or in the absence of myocardial necrosis. “Ischemia-modiﬁed albumin” (IMA), a form
of albumin displaying reduced cobalt-binding aﬃnity, is signiﬁcantly elevated in ischemic patients, and the
albumin cobalt-binding (ACB) assay can measure its level indirectly. Elucidating the molecular mechanism
underlying the identity of IMA and the ACB assay hinges on understanding metal-binding properties of albumin.
Albumin binds most metal ions and harbours four primary metal binding sites: site A, site B, the N-terminal site
(NTS), and the free thiol at Cys34. Previous eﬀorts to clarify the identity of IMA and the causes for its reduced
cobalt-binding capacity were focused on the NTS site, but the degree of N-terminal modiﬁcation could not be
correlated to the presence of ischemia. More recent work suggested that Co2+ ions as used in the ACB assay bind
preferentially to site B, then to site A, and ﬁnally to the NTS. This insight paved the way for a new consistent
molecular basis of the ACB assay: albumin is also the main plasma carrier for free fatty acids (FFAs), and binding
of a fatty acid to the high-aﬃnity site FA2 results in conformational changes in albumin which prevent metal
binding at site A and partially at site B. Thus, this review advances the hypothesis that high IMA levels in
myocardial ischemia and many other conditions originate from high plasma FFA levels hampering the binding of
Co2+ to sites A and/or B. This is supported by biophysical studies and the co-association of a range of patho-
logical conditions with positive ACB assays and high plasma FFA levels.
1. Introduction
Myocardial ischemia occurs due to restricted blood supply to the
muscular tissue of the heart (myocardium) resulting in insuﬃcient
oxygen supply. The main cause of this can be the partial or complete
blockage of a coronary artery, and a critical depletion of myocardial
oxygen leads to cell death, or infarction. Diagnosis of myocardial
ischemia typically includes exercise-electrocardiography stress tests,
coronary angiography, and imaging stress-echo tests [1]. While a ple-
thora of cardiac biomarkers have been described for detecting the de-
velopment of other acute coronary syndromes (ACS) [2,3], there are
still few well-deﬁned biochemical markers for identiﬁcation of myo-
cardial ischemia in advance, or in the absence of myocardial necrosis.
One of these biomarkers is based on albumin, the most abundant
protein in blood plasma. So-called “ischemia-modiﬁed albumin” (IMA)
is found to be signiﬁcantly elevated in ischemic patients [2,4–7], and
serves as a biomarker for early detection of myocardial ischemia before
the onset of irreversible cardiac injury [6]. IMA is solely characterised
by its reduced cobalt-binding aﬃnity, which can be measured indirectly
by the Food and Drug Administration-approved albumin cobalt-binding
(ACB) assay [8,9].
In the commercially available ACB test, cobalt(II) chloride (ap-
proximately 1.5 mol equivalents per albumin molecule) is added to a
serum sample, to allow albumin-cobalt binding. Dithiothreitol (DTT), a
metal chelator that forms a coloured complex with Co2+, is then added.
The resulting ill-deﬁned brown DTT-Co2+ product is measured by ab-
sorption spectrophotometry at 470 nm and compared to a serum-cobalt
blank without DTT present. The reduced cobalt-binding capacity of IMA
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leaves more unbound Co2+ to complex with DTT, resulting in higher
absorbance readings [10]. The ACB test has an excellent negative pre-
dictive value, i.e. low IMA readings correspond well to the absence of
myocardial ischemia. However, a severe shortcoming is the high in-
cidence of false positives, i.e. high readings in the absence of ischemia.
After its ﬁrst description [8], the molecular identity of IMA re-
mained elusive. Based on the general assumption that Co2+ would
preferentially bind to an N-terminal site [11–13], eﬀorts to elucidate
the molecular causes of reduced cobalt binding concentrated on this
site. It was hypothesized that ischemia causes the N-terminal end of the
albumin protein to undergo structural modiﬁcations, hence that IMA
corresponded to N-terminally modiﬁed albumin [13]. The structural
modiﬁcations proposed and investigated included cleavage of the ﬁrst
two residues and oxidation [11], which were suggested to result from
free radical damage, exposure to free iron and copper, or disruption of
ion pumps [8,14].
However, in-depth studies could not reveal a correlation between N-
terminal modiﬁcations and ACB readings [13,15]; more recently, no
correlation was found between the ACB assay and an enzyme-linked
immunosorbent assay that speciﬁcally detects N-terminal modiﬁcation
of albumin in patients with either acute coronary syndrome or non-
ischemic chest pain [16]. Similarly, patients suﬀering from acute-on-
chronic liver failure have signiﬁcantly elevated ACB assay readings, but
the same proportion of N-terminally modiﬁed albumin as healthy in-
dividuals [17,18]. In the light of such ﬁndings, low plasma pH as a
result of acidosis, and altered plasma cysteine/cystine ratio as a con-
sequence of hypoxia or oxidative stress have also been suspected as
molecular causes of reduced cobalt binding [19]. The need to consider
the contribution of other plasma components to the Co-DTT complex
formation was also highlighted [19]. Indeed, a positive correlation has
been identiﬁed between the highly elevated serum levels of free fatty
acids (FFAs) in patients with acute ischemic myocardia and high levels
of IMA [20]. Following our discovery of FFA-mediated inhibition of
zinc binding to albumin [21–24], we have demonstrated that the con-
formational changes that FFA-binding to albumin elicits in the protein
is suﬃcient to cause reduced cobalt binding capacity [22,25]. This re-
view will present essential background information on metal ion-al-
bumin interactions and discuss the molecular basis of FFA-mediated
inhibition of metal (in particular Co2+) binding. It will also provide a
clinical perspective to highlight how conclusions from biochemical/
bioinorganic investigations are reﬂected in patient data.
2. Albumin – a carrier of essential and xenobiotic metal ions in
plasma
Albumin is a ∼66 kDa protein containing 585 amino acids, con-
tributing to around 50% of the total protein concentration in blood
plasma, and up to 75% of the colloidal activity [26]. Albumin comprises
three homologous but structurally distinct domains, each divided into
two sub-domains [27]. One of its key roles in the body is to transport a
variety of small molecules, including cholesterol [28], fatty acids [29],
and pharmaceutical drugs [30]. Importantly, albumin also serves as an
important carrier of inorganic ions, including those required for regular
physiological function (Ca2+, Cu2+, Zn2+) [31], toxic metal ions (Cd2+
and Ni2+) [32,33], as well as metal-based therapeutics (Au+ and Pt2+)
[34,35]. Before considering cobalt binding in depth, we will brieﬂy
summarise the interactions of albumin with other d-block metal ions,
with the exception of Cr3+, Fe3+, and Mn2+, which are preferentially
transported by transferrin, another important metal ion transporter in
blood plasma. Whilst Fe3+ can, in principle, also bind to albumin, this
only occurs in cases of severe iron overload [34].
2.1. Metal binding sites in serum albumins
Though originally albumin was thought to transport ions in a non-
speciﬁc ‘sponge-like’ manner [30], four partially selective metal
binding sites have been identiﬁed, namely the N-terminal site (NTS),
sites A and B, and Cys34 (Fig. 1) [34]. Metal binding to such sites can be
studied using a variety of techniques. Stability constants for the binding
of d-block metals, including Zn2+, Cu2+, Ni2+ and Cd2+, were ori-
ginally derived from equilibrium dialysis experiments [36-39]; more
recently, isothermal titration calorimetry (ITC) has provided valuable
thermodynamic data for metal ion binding [40]. Nevertheless, both of
these techniques only provide global binding constants [34] and need
to be complemented by techniques that address structural features. For
true transition metal ions such as Cu2+ and Co2+, electronic spectro-
scopic methods such as circular dichroism allow metal binding to al-
bumin to be studied via transfer of chirality from metal-binding amino
acid residues to the d-d/charge-transfer bands of complexed metal ions,
providing insight into the geometry of metal-protein interactions
[41,42]. The same ions have unpaired electrons, and can also be in-
vestigated using electron paramagnetic resonance (EPR) spectroscopy,
which provides insight into the chemical environment surrounding the
metal ion [43,44]. To obtain structural information on the binding of
diamagnetic d10 ions, such as Zn2+ and Cd2+, that are largely silent in
the aforementioned spectroscopies, nuclear magnetic resonance (NMR)
methods have been employed, making use of either partially-char-
acterised 1H-resonances of metal-binding residues, or NMR-active nu-
clei such as the 111Cd or 113Cd isotopes of cadmium [39,45–47]. Further
information on the coordination mode, geometry and identiﬁcation of
likely donor ligands has been gained using extended X-ray absorption
ﬁne structure spectroscopy (EXAFS) [47]. In addition, mass spectro-
metry has been used as a tool to detect crosslinking of His67 and His247
by platinum in site A [48].
2.1.1. The N-terminal binding site (NTS)
One of the ﬁrst metal binding sites to be identiﬁed on albumin was
the N-terminal binding site (NTS), which arises from the ﬁrst triplet
amino acid motif of human albumin: Asp1–Ala2–His3 (Figs. 1 and 2)
[49]. It involves the N-terminal amino group, the N(delta) of His3, and
Fig. 1. Location of the three metal binding sites that have
been successfully identiﬁed on human serum albumin,PDB:
5IJF [60]. Site A, the multi-metal binding site (MBS) (blue);
NTS/ATCUN motif (green); Cys34 (red). The precise location
of site B is not yet known. The boxed labels indicate the six
sub-domains of albumin. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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two deprotonated backbone amide nitrogen atoms. This square planar
conﬁguration of N-donor atoms (Fig. 2) is particularly suitable for Cu2+
and Ni2+, which has led to the NTS being referred to by the acronym
‘ATCUN’, for the Amino Terminal Cu(II) and Ni(II) binding motif
[42,50]. The ATCUN motif is present in the majority of albumins from
diﬀerent mammalian species, though porcine and canine albumins are
notable exceptions, as they lack His3 [34]. Oligopeptide models of the
native ATCUN motif have been investigated extensively [34]. The NTS
motif is thought to have high conformational ﬂexibility in the absence
of bound metal, reﬂected in the crystal structures of albumin, all of
which lack deﬁned structures of the ﬁrst few N-terminal residues [12].
Interestingly, the N-terminal X-X-His motif is not unique to albumin –
many other proteins, such as the peptide hormone Hepcidin, can also
bind Ni2+ and Cu2+ ions via an ATCUN motif [51].
Cu2+ binds preferentially to the NTS in albumin, occupying ap-
proximately 1–2% of the available NTS – equating to around 15% of
total copper in blood plasma [34,52]. Owing to the d9 electronic con-
ﬁguration of Cu2+, preference to form square planar complexes, and
high stability in the Irving-Williams series, Cu2+ is coordinated at the
NTS with 1 pM aﬃnity [52], and binds preferentially over other metal
ions [22]. Cu2+ can also bind at other metal binding sites with com-
parable or even higher aﬃnities to those of Ni2+ and Zn2+ [41],
however its low relative concentration (10–20 µM total Cu2+, and sub-
micromolar ‘free’ Cu2+ in plasma) [53] compared to albumin means
that, in practice, only the NTS is ever occupied by Cu2+ [52]. Like
Cu2+, Ni2+ binds to albumin preferentially at the NTS site [33], with
micromolar aﬃnity [34]. Ni2+ is only present at nanomolar con-
centrations in plasma, however levels may be elevated under certain
pathological conditions (e.g. stroke) [54]. Nearly all of plasma Ni2+ is
albumin-bound [12,34]. Binding of Ni2+ and Cu2+ can be modulated
by the redox state of Cys34 [43] with higher metal aﬃnity in the re-
duced (free thiol) state.
Site A – the multi-metal binding site
Metal binding site A is located at the interface of domains I and II
[34] (Fig. 1), and has been identiﬁed and characterised using 1H and
111/113Cd NMR spectroscopy [39,45,46,55,56], circular dichroism, site-
directed mutagenesis [56], EXAFS [47] and recently X-ray crystal-
lography [57]. As well as having a high nanomolar aﬃnity
[23,24,38,39,47] for the d10 divalent cations Zn2+ and Cd2+, site A can
also bind Cu2+, Ni2+ and Co2+ – hence it is also referred to as the
‘multi-metal’ binding site [34,41,56]. In fact, up to 90% of the total zinc
present in plasma (11.5–36.7 µM total Zn2+ in adults [58]) is bound to
albumin [59,60]; this amounts to ca. 98% of exchangeable plasma zinc.
EXAFS, site-directed mutagenesis and molecular modelling initially
suggested that site A is formed by His67, His247, Asp249, and Asn99
[47], and so distorted trigonal bipyramidal coordination of Zn2+ was
proposed, with water (or chloride) as the ﬁfth ligand completing the
inner coordination sphere. However, the recent X-ray crystallographic
structures of human and equine albumins discounted participation of
Asn99 and showed site A to be essentially tetrahedral (Fig. 2), with the
fourth ligand being a water molecule [57]. Cu2+ coordination at site A
had also been suggested to be tetrahedral in geometry, as determined
by EPR and CD experiments [61]. The combination of amino acid re-
sidues bearing intermediate-to-hard N/O-donors [60] (HSAB principle)
provide a good coordination environment for metal ions with a small
ionic radius and moderate charge (e.g. 2+ cations). Notably though, the
aﬃnity of site A for Cu2+ is 4 orders of magnitude lower than that of
the NTS [34], thus site A only becomes populated by Cu2+ when more
than one molar equivalent of Cu2+ is present. Finally, the comparison
of apo- and Zn-bound crystal structures of albumin has revealed high
structural similarity at site A. Thus, in marked contrast to the ﬂexible
NTS, site A is essentially ‘pre-formed’ for metal binding [57,60]. It is
important to note that site A is an inter-domain site, with His67 from
domain I, and His247 and Asp249 from domain II.
Site B
The other Cd2+ binding site (site B), which is distinct from site A
and the NTS and readily identiﬁable using 111Cd or 113Cd NMR
(Fig. 3a), appears to bind Cd2+ with similar aﬃnity to the multi-metal
binding site A [45,46]. In contrast, site B's aﬃnity for zinc is markedly
less than that of site A. Based on NMR data, it is likely that only one
nitrogen donor ligand is involved at site B, suggesting this site to be
harder (HSAB principle) than site A. The location of site B has remained
elusive, but site-directed mutagenesis of His39Leu excluded His39 from
involvement in either site A or B [47].
Cysteine-34
Albumin contains 17 disulﬁde bonds, which contribute to the
structural stability of the protein. One free thiol residue (Cys34) is lo-
cated between helices 2 and 3 of subdomain IA (Fig. 1) [34]. Cys34 is
not involved in any intramolecular bridging, however it often forms
intermolecular disulﬁdes with small sulfur-containing molecules such
as cysteine and glutathione [34]. Under normal physiological condi-
tions, approximately 40% of albumin contains ‘reduced’ Cys34 (free
thiol) [34]. The restricted location of Cys34 in a crevice of albumin
helps to improve its speciﬁcity for binding metal ions that favour linear
coordination, including Hg2+, Au+, Ag+ and Pt2+[34,35], but not
Cd2+ or Zn2+ [56].
Calcium binding sites
Albumin is an important transporter of Ca2+ in blood plasma. Many
reports suggest that this occurs in a non-speciﬁc fashion, involving
various carboxylate side chains on the surface of albumin [42,62],
while work by Majorek et al. detected three deﬁned Ca2+ binding sites
on bovine albumin [63]. It may be signiﬁcant that one of the Ca2+ sites
detected by crystallography involves the key site A ligand, Asp248
(corresponding to Asp249 in human albumin) and indeed, Ca2+ ions
were found to interfere with the 113Cd signals for both sites A and B of
human albumin [46]. However, the aﬃnity of albumin for Ca2+
binding is relatively weak (Kd of 0.67mM), with only around 45% of
Fig. 2. Contrasting geometries of metal binding sites on albumin. Left: square
planar coordination of Cu2+ or Ni2+ at the NTS site; the structure shown is
derived from molecular modelling. The N-terminal amino group, two depro-
tonated backbone amide N atoms and the N(delta) of the imidazole ring of His3
form a square plane around the central metal ion. Right: tetrahedral co-
ordination of Zn2+ at site A in human serum albumin (pdb 5ijf). His67 uses its
N(epsilon) N atom, whilst His247 binds via N(delta). Asp249 binds in mono-
dentate fashion, with the second carboxylate O at ca. 2.6 Å distance, too long
for a metal-ligand bond. Typically for zinc sites in proteins, angles between
ligands deviate substantially from the ideal tetrahedral angle (109.5°) and vary
between 95° and 125°. Metal ions are rendered in gold, N atoms in blue, O
atoms in red, carbon atoms in grey. No H atoms are shown.
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the 2.4 mM of circulating Ca2+ bound to albumin [63,64]. Mg2+,
which is also carried by albumin, is thought to bind to the same binding
sites as Ca2+ but with an even lower aﬃnity (Kd of 10mM) [65].
2.2. Cobalt binding to albumin
Cobalt circulates in the blood as Co2+ and albumin is its principal
transporter in plasma [34]. While it is widely assumed that its binding
resembles that of Ni2+ and Cu2+ (d8 and d9 metal ions, respectively,
with preference for the formation of square planar/tetragonal com-
plexes), Co2+ (d7) behaves in fact more like Zn2+ (d10), has a similar
ionic radius (0.58 vs. 0.60 Å for Zn2+ [66]), and shares a preference for
tetrahedral, penta-coordinate or octahedral geometry [67]. For pre-
cisely this reason, Co2+ has been used extensively as a spectroscopic
probe for Zn2+in proteins [68,69].
In total, three signiﬁcant Co2+ binding sites have been identiﬁed on
albumins – the NTS, site A and site B [42]. Based on Co2+ perturbing 1H
NMR resonances for the three N-terminal residues [11] and Co2+
binding to an ATCUN peptide mimic [13,49], it was assumed that the
primary cobalt-binding site was the NTS motif [11,19,70]. More recent
comprehensive studies on human albumin by Mothes and Faller [71]
and Sokolowska et al. [42], and on bovine albumin by our labs [25]
have since rejected this claim. Competition with Cd2+ and Cu2+
monitored by electronic absorption spectroscopy strongly suggested
that sites A and B are the preferred Co2+ binding sites [16,42,71].
Subsequently, ITC and spectroscopic studies identiﬁed site B as the
strongest cobalt binding site [42]. Co2+ binding to sites A and B was
also conﬁrmed by 111Cd NMR spectroscopy for bovine albumin
(Fig. 3a), and competition with Zn2+ was evident from ITC (Fig. 3b)
[25]. In contrast, blocking the NTS site with Cu2+ did not impart any
signiﬁcant eﬀect on Co2+ binding [25,71]. It is important to note
however, that even though Co2+ and Zn2+may be regarded as metal
ions with similar properties, the apparent binding constant for Co2+
binding to its strongest site on bovine albumin (log
Kapp= 4.6 ± 0.3× 104 M−1; Fig. 5b; [25]) and 9 ± 5×104 M−1 for
human albumin [42]) were around one order of magnitude lower than
those determined for Zn2+ [25].
In summary, even though all three apparent binding constants for
Co2+ binding to human albumin lie between 9 ± 5×104 M−1 and
0.9 ± 0.3× 104 M−1 [42], and hence the respective equilibria do
overlap, the NTS site is now known to have the weakest aﬃnity for
Co2+ [42]. Most importantly, this weaker than anticipated binding of
Co2+ to the NTS means that the initially proposed molecular basis of
the ACB assay to assess the likelihood of myocardial infarction required
revision, since the original studies assumed that Co2+ binds exclusively
to the NTS [8,19].
3. Free fatty acid binding to albumin and allosteric inhibition of
metal ion binding
Albumin has an unparalleled capacity to bind and transports a range
of organic molecules under physiological conditions [72]. Notable
among those transported are FFAs, important substrates in organismal
metabolism for which albumin is the main carrier [73–76]. FFAs are the
main source of energy for heart and skeletal muscle. Disturbances of the
levels and/or distribution of fatty acids in the body have been linked to
a spectrum of pathological disorders, including diabetes, cardiovascular
and neurological diseases, and cancer [77]. Owing to the abundance of
albumin in plasma, and the importance of fatty acids in metabolism and
disease progression, binding of FFAs to albumin has been studied in-
tensively in the past four decades [73], in particular by X-ray crystal-
lography [75,78,79] and 13C NMR spectroscopy [80,81].
Up to seven medium-to-long chain (C10-C18) fatty acid binding
sites (FA1-7) have been identiﬁed on albumin, spread over the three
domains (see Table 1 and Fig. 4) [75]. The binding aﬃnities depend on
both the site and the FFA chain length. Four additional binding loca-
tions have been described for short-to-medium chain fatty acids [82],
however for the purposes of this review we will focus on FA1-7 (Fig. 4).
In a normal physiological state, albumin circulates with between 0.1–2
equivalents of FFAs bound, however it pathologically can bind in excess
of 6 equivalents [83]. The seven identiﬁed binding sites can be broadly
split into two categories: the high-aﬃnity sites (FA2, FA4 and FA5) and
the low-aﬃnity sites (FA1, FA3, FA6 and FA7) [83]. The high-aﬃnity
site FA2 is close to metal-binding site A and therefore of particular
interest. This relatively hydrophobic site is, like metal site A, an inter-
domain site and is located between sub-domains IA and IIA (Fig. 4)
[82]. Compared to FFA-free albumin, accommodation of a fatty acid
molecule in site FA2 requires a change in the mutual arrangement of
domains I and II. While short-chain FFAs (<C8) were originally
thought to be too short to successfully dock in the FA2 site [82], more
recent 1H and 111Cd NMR studies indicated that octanoate can bind to
this site. Molecular modelling suggested that the half-pocket in domain
II is suﬃcient to accommodate octanoate, and therefore does not re-
quire the domain-domain movement [25].
While metal site A is essentially ‘pre-formed’ for metal (physiolo-
gically Zn2+) binding in FFA-free albumin [60], this is not the case
when FA2 is occupied by a longer chain FFA (e.g.myristic acid, C14), as
the distance between the metal-coordinating residues is too large after
Fig. 3. Co2+ competes with both Cd2+ and Zn2+ for albumin
binding under physiological conditions (pH 7.4, 50mM Tris-
Cl, 50mM NaCl) but not with Cu2+. (a) 111 Cd NMR spectra
of Cd2BSA (1.5mM) with increasing addition of Co2+. 111-Cd
resonances corresponding to both site A and B (∼140 ppm
and 35 ppm, respectively) are aﬀected by Co2+. (b)
Isothermal calorimetry experiments performed in the presence
of 1 mol. equiv. of Cu2+ (●) or Zn2+ ( ) demonstrate that
addition of Zn2+ decreases albumin's aﬃnity and capacity for
Co2+-binding, while addition of Cu2+ has no signiﬁcant ef-
fect.
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the conformational change [21,24,56]. This crucial discovery suggested
that FFA and zinc concentration(s) in blood plasma may be correlated
through an allosteric mechanism based on albumin [21,22]. Competi-
tion experiments monitored by ITC demonstrated that the zinc-binding
capacity of both bovine and human albumin for site A was dramatically
reduced [23,25]. Five equivalents of myristate were suﬃcient to com-
pletely inhibit Zn2+coordination to site A in bovine albumin (Fig. 5a),
with site B also aﬀected more or less severely [25]. Importantly, FA2 is
one of the high aﬃnity sites, and will become signiﬁcantly populated
already at 1 molar equivalent [83,84]. Indeed, the data in Fig. 5a in-
dicate that the largest eﬀect is seen between 0 and 2 molar equivalents.
The downstream implications of this allosteric switch for the fate of
plasma zinc are discussed elsewhere [21–23].
Crucially, although the binding preferences of Zn2+ and Co2+ are
not identical, the presence of myristate also clearly reduced the binding
capacity of bovine albumin for Co2+ (Fig. 5b) [25]. The eﬀect on Co2+
binding is less severe than that on Zn2+ binding, with 5 molar
equivalents of myristate reducing binding by ca. 50% [25]. This is in
agreement with the fact that Co2+ does not bind preferentially to site A,
but site B (which in BSA is aﬀected by FFA binding, but less severely)
[25], and can also bind to the NTS motif which is not expected to be
adversely aﬀected by the presence of FFA. Similarly to Zn2+, it appears
that the bound metal ion must ﬁrst be removed from site A before fatty
acid binding can occur at FA2, identiﬁed by a reduction in the exo-
thermicity of the FFA-binding reaction (Fig. 5c) [25]. The number of
apparent Co2+ binding sites in these experiments was in broad agree-
ment with other experimental data, although we note that the selected
experimental conditions did not allow to fully saturate all three binding
sites. The apparent number of binding sites in the absence of myristate
amounted to 2.4, and reduced to ca. 1.3 sites, implying that (at least)
one binding site became non-functional (Fig. 6a). This is consistent with
an inhibition of cobalt-binding to site A, as a result of FFA binding to
the nearby FA2 site [25]. Most importantly, increasing the levels of FFA
in a mock ACB assay is suﬃcient to lead to increased formation of the
Co-DTT product, with concomitant higher absorbance readings
(Fig. 6b). The magnitude of the changes in absorbance at 470 nm is
broadly in line with eﬀects seen in clinical studies [25]. We next explore
whether this molecular mechanism may be reﬂected in clinical data.
4. Ischemia-modiﬁed albumin in disease states
As indicated previously, the diagnostic speciﬁcity of the ACB assay
is very low, resulting in a high proportion of false positives, i.e. high
readings despite the absence of ischemia [15,85]. This realisation has
motivated a large number of studies which found positive ACB readings
for a wide range of disease conditions including ACS [20, 86], chronic
liver and kidney diseases [87,88], infectious diseases such as malaria
[89], and pregnancy-related conditions such as pre-eclampsia [90]. In
addition, elevated IMA levels have been measured in metabolic syn-
drome [91,92], diabetes [93] and obesity [94,95] while exercise and
trauma have also been investigated [96,97]. These conditions, there-
fore, should have a common feature that can explain elevated IMA le-
vels, and we propose that this common feature is elevated plasma FFAs.
The latter have been shown to independently inﬂuence the ACB assay to
the same extent as ACS and other conditions [20,25]. Together with the
biochemical and biophysical studies detailed in Section 3, it is com-
pelling to suggest that IMA corresponds to albumins in which FA2 is
occupied. To further explore this hypothesis, Table 2 compiles selected
conditions which are positive for the ACB assay and reports quantita-
tive data on serum FFAs drawn from the literature. Cobalt binding to
albumin is both speciﬁc and proportional to the total serum albumin
concentration, and so many studies adjust for the total albumin level
[10].
ACSs are well-known to be associated with increased serum FFA
concentrations [20,98]. The pain and the stress associated with such
syndromes is thought to trigger a sympathetic discharge, with the re-
lease of catecholamines which activate hormone-sensitive tissue lipase
– the enzyme which hydrolyses triglycerides and hence liberates FFAs
into the circulation [99–101]. This leads to elevated serum free fatty
acid concentrations within 1–2 hours from the onset of ACS, and the
degree of increase in FFA concentration has been positively associated
with serious ventricular arrhythmias [102]. Signiﬁcantly, the ACB assay
values are also positively correlated to the severity of the ACS condition
[20,86,102]. In addition, the IMA levels detected via the ACB assay
Table 1
The location and characteristics of fatty acid binding sites FA1-7 of albumin. Particular attention is drawn to binding site FA2, since occupation of this site by FFAs
causes an allosteric switch in metal binding at site A, owing to its close proximity; both are located between subdomains IA and IIA.
Site Aﬃnity Physiologicala Subdomain Comments Reference
FA1 Low – IB Site is relatively accessible to solvent [79,82]
FA2 High Yes IA-IIA Allosteric switch aﬀecting site A [21,82,83]
FA3 Low – IIB-IIIA Chain distorted in longer FFAs [78,82]
FA4 High Yes IIIA Inverted conﬁguration for C18 FFAs [82,83,143]
FA5 High Yes IIIB C18 FFAs accommodated [82,83]
FA6 Low – IIA-IIB Absence of ligands for carboxylate [78,79,82]
FA7 Low – IIA Preference for shorter-chain FFAs [78,82]
a (Partially) Occupied under basal physiological conditions (pH 7.4, 0.5–2mol. equiv. of FFA).
Fig. 4. (a) Location of fatty acid (FFA) binding sites FA1-7 on
human serum albumin (PDB: 1E7H), complexed with hex-
adecanoic (palmitic) acid [82]. High (magenta) and low
(green) aﬃnity sites are shown. (b) Location of site A, the
multi-metal binding site (PDB: 5IJF), occupied by Zn2+ (blue)
[57]. Site A and FA2 are both located between subdomains IA-
IIA. The inter-domain nature and the proximity of FA2 to site
A allows for the allosteric switching of metal ion binding [21].
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increase within minutes of the onset of ischemia, stay high for 6 to 12
hours before returning to normal level within 24 hours. This correlates
to similar changes in FFA levels, which return to normal after 24 to 48
hours after myocardial ischemia [103], but is in contrast to explana-
tions invoking N-terminally modiﬁed albumin, as albumin has a half-
life of ca. 20 days and so IMA should be detected for several days fol-
lowing ischemia [104,105].
Higher FFA concentrations in plasma have been observed in several
non-communicable diseases which also result in a positive ACB assay
[22]. In fatty liver disease for example, there is insulin resistance which
causes a withdrawal of the inhibition of dephosphorylation of hormone-
sensitive lipase activity to reduce fat hydrolysis [106–108]. Further to
this, the capacity of the liver to utilise and export FFAs is impaired,
leading to increased FFAs in the circulation [87,109,110]. Similarly,
chronic kidney disease is associated with raised FFA concentrations
arising from TNF-α-induced adipose tissue lipolysis as a consequence of
systemic inﬂammation [111,112]. In addition, when patients suﬀering
from metabolic syndrome are given high-fat diets, a signiﬁcant increase
of their IMA/albumin ratio occurs [113]. It is therefore consistent with
our hypothesis that those disease states are associated with positive
ACB assays. Further conditions with positive ACB readings include
diabetes [114], hypothyroidism [115], intrauterine growth restriction
[116], chronic inﬂammation (rheumatoid arthritis [117] and anky-
losing spondylitis [118]), infection (sepsis [119] and malaria [89]),
exercise [96] and trauma [97]. All of these are also associated with high
FFA concentrations (see Table 2) through various physiological and
pathophysiological pathways [120–125].
However, for some other conditions associated with high IMA levels
(psoriasis [126] and polycystic ovarian syndrome [127]) no variation in
FFA levels compared to healthy controls have been found. Yet some
speciﬁc long-chain FFAs were measured at higher concentrations and
their increased binding aﬃnity for albumin may explain the observed
changes in albumin metal-binding capacities [82]. For other conditions
(obstructive sleep apnoea syndrome [128], ovarian torsion [129], mo-
thers bearing small-for-gestational-age foetuses [116] and preterm ba-
bies with respiratory distress syndrome [130]), FFA levels have not yet
been measured. Several other studies detected higher IMA levels in yet
more conditions (hyperemesis gravidarum [131], perinatal asphyxia
[132], mild cognitive impairment [133], pre-eclampsia [90]), however
they were not included in our analysis as “IMA levels” were measured
with an immunoassay (see next section) instead of the ACB assay.
5. Proposed alternatives to the ACB assay
An enzyme-linked immunosorbent assay has been developed as an
alternative to the ACB assay to speciﬁcally detect N-terminal mod-
iﬁcation of albumin. However, no correlation has been found between
the results of this assay and IMA levels measured via the ACB assay in
patients with either acute coronary syndrome or non-ischemic chest
pain [16]. This is consistent with metal binding sites A and B playing a
more important role in cobalt binding than the N-terminus.
Other studies on human serum albumin have utilised Cu2+ and
Ni2+ instead of Co2+to assess reduced metal binding. In some cases,
these studies were inspired by the originally proposed mechanism in-
volving binding to the NTS [134–136]. Even though Cu2+ and Ni2+ do
indeed preferentially bind to the N-terminus, these studies were suc-
cessful in demonstrating poor binding capacity of albumin for these
ions in coronary artery syndromes – similar to the ACB assay
[134–136]. It should however be considered that site A is a potent
secondary binding site for these metal ions once the NTS is saturated, as
Fig. 5. Isothermal titration calorimetry experiments
demonstrate the mutual modulation of metal and fatty
acid binding to bovine albumin. The presence of the
C14:0 fatty acid myristate (○, 0 mol. equiv.; ●, 1 mol.
equiv.; ▽, 3 mol. equiv.; and ★ 5mol. equiv.) aﬀects
the binding capacity of albumin for Zn2+ (a) and Co2+
(b) under near-physiological conditions (pH 7.4,
50mM Tris-Cl, 50mM NaCl). Co2+ binding to albumin
is not only weaker than that of Zn2+, but the eﬀect of
FFAs on Zn2+ binding is also much more pronounced
than that of Co2+. (c) The presence of 1mol. equiv. of
Zn2+ ( ) or Co2+ (●) aﬀects the energetics of fatty
acid binding relative to the metal-free experiment (○),
likely due to the need to remove the metal before the
FFA can bind. Notably, again the eﬀect for Zn2+ is
larger than that for Co2+.
Fig. 6. Increasing FFA (myristate, C14:0) decreases the total Co2+ binding capacity of BSA, (a) reﬂected in the number of apparent binding sites of albumin for Co2+
(No data for 4mol. eq. Myr). (b) In turn, this aﬀects the formation of the Co-DTT complex as part of the ACB assay (b), used for the detection of myocardial ischemia.
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explained in Section 2 [34,137,138]. Therefore, providing that such
tests employ an appropriate metal: albumin molar ratio (≥2), FFAs can
aﬀect the binding capacity of albumin for Cu2+ and Ni2+ binding to
site A (and site B) like for Zn2+ or Co2+ [8,22,135]. Most recently, a
13C NMR-based protocol using 13C-methyl-labeled oleic acid (OA) as a
reporter molecule has also been developed to measure the amount of
long chain FFAs bound to albumin as an alternative to the ACB assay
that is not dependent on total albumin concentrations [139].
6. Conclusion
Use of the ACB assay to measure IMA levels in multiple pathological
conditions has gained traction in recent years. The diagnostic value of
this test critically depends on understanding its molecular basis. In the
light of compelling evidence, there is now increasing recognition of the
fact that N-terminal modiﬁcation is not a plausible explanation for re-
duced cobalt binding by albumin [16,139,140]. Nonetheless, the FFA-
based mechanism is not yet widely accepted either, with many recent
studies claiming that IMA corresponds to a marker for “oxidative
stress”. In principle, an altered redox balance may well aﬀect the ill-
deﬁned chemistry of complex formation between Co2+ and DTT, as
both agents are prone to oxidation. This alternative hypothesis which
does not require covalent modiﬁcation of albumin may also be more
compatible with the timescales of increased and returned to normal
ACB readings. At present, corresponding quantitative data and experi-
ments to demonstrate the viability of this hypothesis are scarce, and it
leaves unclear the role of albumin in the readout, although the possi-
bility of ternary complex formation was raised [19]. The correlation
between ACB assay readings and FFA levels is clear (Fig. 6b), provides a
coherent explanation of the chemical identity of IMA, and is consistent
with all clinical observations. Serum FFA, in particular unbound FFA,
concentrations are useful biomarkers for early diagnosis of ACS [141].
We suggest that the ACB asay – or indeed one of its variants using other
metal ions – may be re-purposed as a test for increased serum FFAs
[22,25,140,142]. A comprehensive understanding of the chemical
species contributing to the overall readouts, including eﬀects of pH and
redox chemistry, should enable the design of a test with much better
speciﬁcity and diagnostic value.
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